Orphazyme CFO on failed trial: "Highly disappointing and highly surprising"

Monday's announcement that Orphazyme's main candidate, arimoclomol, for treating degenerative muscle disease IBM has not met its effect targets is highly disappointing and surprising, says the firm's CFO. Now, the company considers scaling back its efforts in the area.
Orpazyme CFO and interim CEO Anders Vadsholt. | Photo: Orphazyme / PR
Orpazyme CFO and interim CEO Anders Vadsholt. | Photo: Orphazyme / PR
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

"This is highly disappointing and and highly surprising."

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading